Company Overview

Alector, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases and certain forms of cancer through modulation of the immune system. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immuno-neurology, a field that combines immunology and neuroscience to address diseases such as Alzheimer’s disease, frontotemporal dementia (FTD), and other neurodegenerative conditions. Alector’s core strategy centers on targeting innate immune pathways, particularly microglial function in the central nervous system, to influence disease progression rather than only treating symptoms.

The company’s primary revenue sources have historically included collaboration agreements, research funding, and licensing arrangements, particularly its strategic partnerships with GlaxoSmithKline plc (GSK) and AbbVie Inc. Alector was founded in 2013 by Arnon Rosenthal, Gary Romano, and Wim Parys, and is headquartered in South San Francisco, California. Since its founding, the company has evolved from an early-stage research platform into a publicly traded biotechnology company advancing multiple clinical-stage therapeutic candidates, including progranulin-elevating therapies and TREM2-targeting antibodies designed to address genetically defined neurodegenerative disorders.

Business Operations

Alector conducts operations primarily through research and development activities focused on therapeutic antibody discovery and clinical development. The company’s pipeline includes programs such as latozinemab (AL001), a progranulin-elevating antibody candidate for frontotemporal dementia associated with progranulin gene mutations, and AL101/GSK4527226, developed in collaboration with GSK for Alzheimer’s disease and other neurodegenerative conditions. The company generates revenue largely through collaboration agreements, milestone payments, and research support from pharmaceutical partners rather than commercial product sales, as it does not yet have approved therapies on the market.

Operationally, Alector maintains a predominantly U.S.-based footprint but engages in international clinical development activities through global trial sites and strategic partnerships. The company controls proprietary immuno-neurology discovery platforms focused on innate immune pathways and antibody engineering technologies. Major collaborations include partnerships with GlaxoSmithKline plc and AbbVie Inc., which have supported co-development and commercialization efforts for select pipeline assets. Alector’s activities are heavily concentrated in clinical development, translational medicine, biomarker research, and regulatory advancement of its therapeutic candidates.

Strategic Position & Investments

Alector’s strategic direction is centered on advancing immuno-neurology as a differentiated therapeutic approach for neurodegenerative disease. The company has prioritized genetically validated disease targets and biomarker-driven development strategies intended to improve clinical trial precision and therapeutic efficacy. Its growth initiatives have included expanding late-stage clinical development programs, strengthening partnerships with large pharmaceutical companies, and broadening applications of innate immune modulation across multiple neurodegenerative indications.

The company has invested substantially in research capabilities, clinical infrastructure, and antibody-based therapeutic platforms. Strategic partnerships with GSK and AbbVie have enabled access to development funding, global commercialization expertise, and expanded research collaboration opportunities. Alector has also positioned itself within emerging areas of neuroimmunology and precision medicine by focusing on microglial biology, progranulin pathways, and TREM2 receptor modulation. Public filings and investor disclosures indicate continued prioritization of therapies for Alzheimer’s disease, frontotemporal dementia, and related disorders where unmet medical need remains significant.

Geographic Footprint

Alector is headquartered in South San Francisco, California, and its core operations are concentrated in the United States. The company conducts research, development, and corporate operations primarily from its California facilities, while leveraging international clinical trial networks and global pharmaceutical partnerships to support broader development efforts.

Through collaborations with multinational pharmaceutical companies and participation in international clinical studies, Alector maintains operational and research exposure across North America, Europe, and selected markets in the Asia-Pacific region. Although the company does not currently operate large-scale commercial infrastructure outside the United States, its development programs and strategic alliances provide international reach and potential future commercialization pathways in major global healthcare markets.

Leadership & Governance

Alector was co-founded by Arnon Rosenthal, who has played a central role in shaping the company’s scientific and strategic direction. The company’s leadership has emphasized translating advances in immunology into treatments for neurodegenerative diseases, with a focus on genetically informed therapeutic development and long-term clinical innovation. Governance oversight is provided through a board structure typical of publicly traded biotechnology companies and guided by disclosures in SEC filings, including annual reports and proxy statements.

Key executives include:

• Arnon Rosenthal – Chief Executive Officer
• Gary Romano – President and Chief Medical Officer
• Mark Genovese – Chief Medical Officer
• Ryan Darby – Chief Financial Officer
• Sara Kenkare-Mitra – President of Research and Development
• Robert King – Chief Legal Officer and Corporate Secretary

The company’s leadership strategy has consistently emphasized scientific collaboration, biomarker-guided development, and partnership-driven advancement of neurodegenerative disease therapeutics.